Physician profile
Timothy Sullivan
NPI 1538486717
$2,883.45
in general payments reported to CMS, 2019-2025
19 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2020: $88.91 · 2021: $442 · 2022: $149 · 2023: $492 · 2024: $494 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327 · Long Term Medical Supply Or Device Loan: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.09 |
| Long Term Medical Supply Or Device Loan | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $533.52 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Aerie Pharmaceuticals, INC. | $456.09 | 2019-2021 | |
| Allergan, INC. | $318.64 | 2019-2021 | |
| Rxsight INC | $265.90 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Ocular Therapeutix, INC. | $243.07 | 2021-2025 | Dextenza |
| Alcon Vision LLC | $229.82 | 2019-2023 | Rocklatan |
| Glaukos Corporation | $183.56 | 2019-2024 | Idose |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $171.68 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $92.71 | 2023-2025 | Vyzulta, Envista Mx60 Iol |
| Regeneron Healthcare Solutions, INC. | $80.89 | 2025 | Eylea Hd |
| Horizon Therapeutics Plc | $79.32 | 2022-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $66.58 | 2019 | |
| Sight Sciences, INC. | $32.47 | 2019-2020 | |
| Harrow Eye, LLC | $30.73 | 2025 | Iheezo |
| Beaver-Visitec International, INC. | $24.77 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.34 | 2019 | |
| Amgen INC. | $20.48 | 2024 | Tepezza |
| Rayner Intraocular Lenses Limited | $16.24 | 2023 | Omidria, Rayone Spheric, Rayone Emv |
| Kala Pharmaceuticals, INC. | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.